Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.

已完结 10 由 wocause 发布于 2026/5/10 21:49:27

DOI:10.1056/nejmoa2510308
作者：Pasi A J?nne,David Planchard,Kunihiko Kobayashi,James Chih-Hsin Yang,Ying Liu,Natalia Valdiviezo,Tae Min Kim,Liyan Jiang,Hiroshi Kagamu,Noriko Yanagitani,Jialei Wang,Bivas Biswas,Artem Poltoratskiy,Ye
文献类型：期刊论文
补充材料：只需要正文

New England Journal of Medicine (NEJM)

Abstract：BACKGROUND The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer prog

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:ElsevierSequence Analysis of the Plutella xylostella Granulovirus Genome